Literature DB >> 31076419

T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors.

Sho Yoneda1, Akihisa Imagawa2, Yoshiya Hosokawa3, Megu Yamaguchi Baden3, Takekazu Kimura3, Sae Uno3, Kenji Fukui3, Kunihito Goto4, Motohide Uemura5, Hidetoshi Eguchi4, Hiromi Iwahashi3,6, Junji Kozawa3, Iichiro Shimomura3.   

Abstract

Entities:  

Year:  2019        PMID： 31076419     DOI： 10.2337/dc18-2518

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  24 in total

Review 1.  Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.

Authors:  Z Quandt; A Young; M Anderson
Journal:  Clin Exp Immunol       Date:  2020-02-28       Impact factor: 4.330

Review 2.  When therapeutic drugs lead to diabetes.

Authors:  Bruno Fève; André J Scheen
Journal:  Diabetologia       Date:  2022-03-04       Impact factor: 10.122

Review 3.  Patient-Centered Diabetes Care of Cancer Patients.

Authors:  Anupam Kotwal; Yee-Ming M Cheung; Grace Cromwell; Andjela Drincic; Houry Leblebjian; Zoe Quandt; Robert J Rushakoff; Marie E McDonnell
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

4.  Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Authors:  Jagdeep Singh; Ranjana Walker Minz; Biman Saikia; Ritambhra Nada; Aman Sharma; Saket Jha; Shashi Anand; Manish Rathi; Sanjay D'Cruz
Journal:  Clin Exp Med       Date:  2022-10-11       Impact factor: 5.057

5.  Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.

Authors:  Artak Labadzhyan; Kristopher Wentzel; Omid Hamid; Kamlynn Chow; Sungjin Kim; Lawrence Piro; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

Review 6.  Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.

Authors:  Brendan L Mangan; Renee K McAlister; Justin M Balko; Douglas B Johnson; Javid J Moslehi; Andrew Gibson; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 4.335

Review 7.  Endocrine toxicities of immune checkpoint inhibitors.

Authors:  Jordan J Wright; Alvin C Powers; Douglas B Johnson
Journal:  Nat Rev Endocrinol       Date:  2021-04-19       Impact factor: 43.330

Review 8.  Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.

Authors:  V Lo Preiato; S Salvagni; C Ricci; A Ardizzoni; U Pagotto; C Pelusi
Journal:  Rev Endocr Metab Disord       Date:  2021-01-06       Impact factor: 6.514

Review 9.  Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review.

Authors:  Michele Porcu; Cinzia Solinas; Cristina Migali; Angelo Battaglia; Marina Schena; Lorenzo Mannelli; Alfredo Addeo; Karen Willard-Gallo; Luca Saba
Journal:  Target Oncol       Date:  2020-02       Impact factor: 4.864

10.  Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional.

Authors:  Akihisa Imagawa
Journal:  J Diabetes Investig       Date:  2020-12-07       Impact factor: 4.232
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.